Skip to main content
OpenTrials
Completed

NCT Number: NCT01876901

Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)

Hypothesis:

In France, approximately 12,000 new rectal cancers are diagnosed each year. Frequency is one and a half times higher in men than in women. The average age of diagnosis is 65. Unlike colon cancer, technical management remains challenging with unresolved operating difficulties. Morbidity of surgical procedures remains high with a very large number of preventive or curative stoma derivations.

Reference in surgical treatment is total excision of the rectum and its mesentery, followed by continuity restoration by immediate coloanal anastomosis (ACAI). In this procedure, rate of fistula that results is reported in the literature between 15 and 25%.

An alternative to ACAI is delayed coloanal anastomosis without reservoir (ACAD). Based on retrospective experiences, we form the hypothesis that ACAD offers a much lower rate of fistula (<5%) and allows diminution of preventive stoma derivation practice. Morbidity and mortality are reduced, and patient's quality of life greatly improved. Direct costs (consumables intraoperative, hospitalization, stoma complications) and indirect (pocket-fitting stoma) are greatly reduced.

This study is a multicentre, two arms, phase 2 clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medium and Lower Rectal Cancer Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases Rectal Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CHU DE BORDEAUX - Hôpital Saint André, Bordeaux, Aquitaine, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven rectal adenocarcinoma.
  • Medium or lower rectum tumour requiring removal of the entire rectum and its mesorectum.
  • T1 N+ or T2 N+ or T3 N+ or T3 N0 and M0 tumour.
  • Age between 18 and 75 years .
  • ASA ≤ 2.
  • Sphincter continence compatible with coloanal anastomosis.
  • Patients who received preoperative radiotherapy alone or chemotherapy and radiotherapy.
  • Patient affiliated to social security.
  • For patients of childbearing age, use of contraception.
  • Patient information and consent for study participation

Exclusion criteria

  • Other histology of rectal cancer.
  • T1 N0 or T2 N0 or T4 tumour.
  • Metastatic disease M1.
  • History of cancer except cervix in situ carcinoma or skin basal cell carcinoma.
  • Patient with psychological, social, family or geographical reasons who couldn't be treated or monitored regularly by the criteria of the study
  • Patients deprived of liberty or under guardianship.
  • Pregnant or nursing women.

Treatment and study plan

2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)

Procedure

2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.

After surgical resection, the colon is exteriorized through the anus and attached to the buttock.

By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation

Colo-anal anastomosis (CAA)

Procedure

After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.

In the absence of fistula, the patient will reoperation for stoma closure of its branch

Primary outcomes

  1. Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA

    Time frame: Delayed coloanal anastomosis effectiveness was evaluated in terms of symptomatic anastomotic fistula occurring during the 30 days post anastomosis and requiring stoma derivation.

    Efficacy of the intervention was defined as the absence at day 30 of a symptomatic AL (either with entero-cutaneous fistula or perianastomotic abscess with infectious conditions and/or transit impairment) requiring diverting stoma (curatively for 2-stage CA or prophylactic-based for CA). AL was defined as fecal matter in the drainage system when a drainage system was present. Clinical signs included fever and subocclusion requiring a pelvic scan and collection of liquid and gas in the peri-anastomotic region. Non-symptomatic ALs which did not require any investigation nor treatment, in particular no diverting stoma, were not considered failures.

    Assuming an efficacy rates of 85% (null hypothesis) and 95% (alternative hypothesis), and relied on a superiority test at the 5% significance level (one-sided) with 80% power, 53 eligible and assessable patients were required. Efficacy of the intervention was concluded if at least 49 patients had no symptomatic AL at day 30.

Secondary outcomes

  1. Stomata Bypass (Preventive or Therapeutic)

    Time frame: Presence of stomata bypass was evaluated at 30 days, 1 year and 2 years after surgery (2SCA or CAA)

    Number of patients with stomata bypass (preventive or therapeutic) at each time of follow-up after surgery (2SCA or CAA).

    A stomata bypass is the result of a surgical operation in which a damaged part is removed from the ileum (ileostomy) or colon (colostomy) and the cut end diverted to an artificial opening in the abdominal wall.

  2. Post-operative Morbidity

    Time frame: During the 30 first days after surgery (2SCA or CAA)

    Post-operative morbidity was assessed in terms number of patients with at least one surgical complications related to treatment and related to a serious adverse event.

  3. Postoperative Mortality

    Time frame: From the date of surgery to 30 days after surgery (2SCA or CAA)

    Postoperative mortality was defined by the number of patients who deceased (all cause mortality) during the first 30 days after surgery (2SCA or CAA).

  4. Progression-free Survival

    Time frame: 1 and 2 years after surgery (2SCA or CAA)

    Progression-free survival (PFS) was defined as the time from the date of surgery and the date of the earliest of the following events:

    • The patient's death, whatever the cause,
    • Local progression or remotely.

    Progression was defined as clinical or radioglogical progression. Radiological progression was defined Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions"

    1-year and 2-year progression-free rates were estimated.

  5. Number of Participants With Anal Incontinence at 6 Months

    Time frame: At 6 months after surgery (2SCA or CAA)

    The digestive functions, especially anal incontinence was evaluated according to the scale of 5 items Jorge and Wexner (score from 0 to 20).

    The rate of patients with anal incontinence (score >=5) at 6 months was reported.

  6. Number of Participants With Anal Incontinence at 12 Months

    Time frame: At 12 months after surgery (2SCA or CAA)

    The digestive functions, especially anal incontinence was evaluated according to the scale of 5 items Jorge and Wexner (score from 0 to 20).

    The rate of patients with anal incontinence (score >=5) at 12 months was reported.

  7. Number of Participants With Anal Incontinence at 24 Months

    Time frame: At 24 months after surgery (2SCA or CAA)

    The digestive functions, especially anal incontinence was evaluated according to the scale of 5 items Jorge and Wexner (score from 0 to 20).

    The rate of patients with anal incontinence (score >=5) at 24 months was reported.

  8. Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA

    Time frame: Colo-anal anastomosis effectiveness will be evaluated in terms of symptomatic anastomotic fistula occurring during the 30 days post anastomosis and requiring stoma derivation.

    Efficacy of the intervention was defined as the absence at day 30 of a symptomatic AL (either with entero-cutaneous fistula or perianastomotic abscess with infectious conditions and/or transit impairment) requiring diverting stoma. AL was defined as fecal matter in the drainage system when a drainage system was present. Clinical signs included fever and subocclusion requiring a pelvic scan and collection of liquid and gas in the peri-anastomotic region. Non-symptomatic ALs which did not require any investigation nor treatment, in particular no diverting stoma, were not considered failures.

    The effectiveness of the CAA surgery will be evaluated in terms of absence of fistula requiring stoma diversion. Similarly to 2SCA group, 53 CAA eligible and evaluable patients will be required. If 49 or more patients (out of 53) have no fistula requiring stoma diversion, then we conclude that the CAA is effective. To anticipate any non evaluable patients, we plan to recruit 58 patients CAA.

Sponsors and collaborators

Lead sponsor

Institut Bergonié

Other

Registry information

Official study title

Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial.

Acronym: CASCADOR

Important dates

Study start
2010
Primary completion
2017
Study completion
2019
First posted
Jun 13, 2013
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.